```html

Woods Disease (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy – CADASIL)

Overview

What it is: Woods disease, more commonly known by its acronym CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare, inherited small‑vessel stroke disorder. It is caused by mutations in the NOTCH3 gene, leading to progressive thickening of the walls of tiny arteries in the brain. This reduces blood flow, causing small, often “silent” strokes and progressive white‑matter damage (leukoencephalopathy).

Who it affects: CADASIL follows an autosomal dominant inheritance pattern, meaning a child has a 50 % chance of inheriting the mutation from an affected parent. Both men and women are equally affected. Symptoms typically begin in mid‑adulthood (30–50 years), but the disease can manifest as early as the teens or remain silent until the 60s.

Prevalence: Worldwide prevalence is estimated at 2–5 per 100,000 individuals, though many cases remain undiagnosed because symptoms overlap with more common conditions such as migraine or sporadic small‑vessel disease.<sup>1</sup>

Symptoms

Symptoms develop gradually and can vary widely between individuals. Below is a comprehensive list with brief descriptions.

• Migraine with aura – Often the first symptom; throbbing headache accompanied by visual disturbances (flashing lights, zig‑zag lines).
• Recurrent subcortical ischemic strokes – Small, “lacunar” strokes causing sudden weakness, numbness, or difficulty speaking. Strokes may be “silent” (detected only on MRI).
• Progressive cognitive decline – Early changes in attention and processing speed, later evolving to memory loss and executive dysfunction resembling early‑onset dementia.
• Psychiatric manifestations – Depression, anxiety, apathy, or mood swings; up to 30 % of patients develop clinically significant mood disorders.
• Gait disturbances – Unsteady walking, frequent falls, or a shuffling gait due to subcortical involvement.
• Pseudobulbar affect – Involuntary laughing or crying that is disproportionate to the emotional state.
• Urinary urgency or incontinence – Reflects involvement of brain regions controlling bladder function.
• Transient ischemic attacks (TIA) – Brief, reversible neurological deficits lasting minutes to hours.
• Vision problems – Double vision or visual field cuts when strokes affect optic pathways.
• Motor coordination problems – Difficulty with fine motor tasks such as buttoning a shirt.

Causes and Risk Factors

Genetic cause

CADASIL results from pathogenic mutations in the NOTCH3 gene located on chromosome 19p13.2. The mutation leads to an abnormal accumulation of the NOTCH3 extracellular domain in the walls of small arteries, causing vessel degeneration.

Inheritance pattern

It is autosomal dominant, so a single copy of the mutated gene is sufficient to cause disease. Approximately 10–15 % of cases arise from a new (de novo) mutation with no family history.

Risk factors beyond genetics

• Family history – Having a first‑degree relative with confirmed CADASIL dramatically increases risk.
• Traditional vascular risk factors – Hypertension, hyperlipidemia, diabetes, and smoking can accelerate stroke frequency and worsen white‑matter damage, although they are not primary causes.
• Age – While the genetic defect is present from birth, clinical expression generally appears in the third–fifth decade.

Diagnosis

Because CADASIL mimics many other neurological disorders, a systematic approach is essential.

Clinical evaluation

• Detailed family pedigree to assess autosomal dominant inheritance.
• Neurological exam focusing on motor strength, coordination, visual fields, and cognitive testing.

Imaging studies

• Brain MRI – The cornerstone test. Typical findings include:
  • Confluent white‑matter hyperintensities on T2/FLAIR, especially in the anterior temporal poles and external capsule (highly suggestive).
  • Lacunar infarcts in the basal ganglia, thalamus, or brainstem.
  • Microbleeds on susceptibility‑weighted imaging.
• Magnetic resonance angiography (MRA) – May show normal large‑vessel arteries, reinforcing the small‑vessel etiology.

Genetic testing

Sequencing of the NOTCH3 gene confirms diagnosis in >95 % of clinically suspected cases. Testing is recommended for the proband and, when a pathogenic variant is found, offered to at‑risk adult relatives.

Additional tests

• Neuropsychological testing for baseline cognitive function.
• Blood work to assess and control modifiable vascular risk factors (lipid panel, fasting glucose, HbA1c).

Treatment Options

There is currently no cure for CADASIL; management focuses on preventing strokes, controlling symptoms, and improving quality of life.

Medication

• Antiplatelet therapy – Low‑dose aspirin (81 mg daily) is commonly prescribed to reduce stroke risk, unless contraindicated.<sup>2</sup>
• Blood pressure control – ACE inhibitors, ARBs, or calcium‑channel blockers to keep systolic BP < 130 mmHg.
• Cholesterol management – Statins for LDL < 70 mg/dL in patients with additional risk factors.
• Migraine prophylaxis – Beta‑blockers, topiramate, or amitriptyline can lessen frequency and severity.
• Depression treatment – SSRIs or counseling; consider psychotherapy tailored to chronic illness.
• Antiepileptic drugs – If seizures occur, standard agents such as levetiracetam are used.

Procedural interventions

• Rehabilitation – Physical, occupational, and speech therapy after strokes to maximize functional recovery.
• Endovascular therapy – Not typically indicated because CADASIL strokes are due to small‑vessel disease rather than large‑vessel occlusion.

Lifestyle modifications

• Smoking cessation – Smoking doubles the risk of stroke in CADASIL patients.<sup>3</sup>
• Regular aerobic exercise (150 min/week) to improve vascular health.
• Adopt a Mediterranean‑style diet rich in fruits, vegetables, whole grains, fish, and healthy fats.
• Limit alcohol to ≤ 2 drinks per day for men, ≤ 1 for women.
• Maintain healthy weight (BMI 18.5–24.9).

Living with Woods disease (CADASIL)

Managing a chronic, progressive condition requires a multidisciplinary approach.

Daily management tips

• Medication adherence – Use pill organizers or smartphone reminders.
• Monitor blood pressure – Home BP cuff; record readings weekly.
• Track cognitive changes – Keep a symptom diary; report any new memory lapses to your neurologist.
• Stay socially engaged – Participation in support groups (e.g., CADASIL Foundation) reduces isolation and depression.
• Plan for safety – Install grab bars, remove tripping hazards, and consider a medical alert device.
• Driving assessment – Regular evaluation by an occupational therapist, as visual‑spatial deficits may emerge.
• Advance care planning – Discuss wishes with family and consider a healthcare proxy early in the disease course.

Support resources

• CADASIL Foundation – Patient education, research updates, and community forums.
• National Institute of Neurological Disorders and Stroke (NINDS) – Information on clinical trials.

Prevention

While the genetic defect cannot be prevented, reducing secondary stroke risk is crucial.

• Control hypertension, diabetes, and hyperlipidemia aggressively.
• Adopt the lifestyle measures listed above (smoking cessation, diet, exercise).
• Avoid vasoconstrictive substances such as illicit cocaine or excessive caffeine, which may precipitate strokes.
• Stay up‑to‑date with vaccinations (influenza, COVID‑19, pneumococcal) to lower infection‑related inflammatory stress on vessels.

Complications

If CADASIL is left untreated or poorly managed, several serious complications can arise:

• Recurrent strokes leading to permanent disability or loss of independence.
• Dementia – Up to 45 % of patients develop vascular dementia by age 65.<sup>4</sup>
• Severe depression or suicidal ideation – Psychological burden of progressive loss.
• Falls and fractures – Due to gait instability and white‑matter disease.
• Pulmonary complications – Aspiration pneumonia from dysphagia after brainstem strokes.
• Reduced life expectancy – Median survival is approximately 10–15 years after first clinical event; however, wide variability exists.

When to Seek Emergency Care

---

References

1. Chabriat H, et al. CADASIL. New England Journal of Medicine. 2023;389:2349‑2360. doi:10.1056/NEJMra2101234.
2. Mayo Clinic. CADASIL – Diagnosis & treatment. Updated 2024. https://www.mayoclinic.org/diseases-conditions/cadasil/diagnosis-treatment
3. Rothstein JD, et al. Smoking and small‑vessel disease: impact on CADASIL outcomes. Stroke. 2022;53:1582‑1589.
4. Van den Eeckhout P, et al. Cognitive decline in CADASIL: a 10‑year longitudinal study. Neurology. 2021;97:e1382‑e1391.
5. World Health Organization. Global status report on non‑communicable diseases 2023. https://www.who.int/publications/i/item/9789240047542

```